2500 Orteronel (Ort) maintenance therapy in patients (pts) with metastatic castration resistant prostate cancer (mCRPC) and non-progressive disease after first-line docetaxel (Doc) therapy: Results of a multicenter randomized double-blind placebo-controlled phase III trial (SAKK 08/11). Issue 3 (September 2015) - Cathomas, R.; Crabb, S.; Kenner, H.; Mark, M.; Rothermundt, C.; Elliott, T.; Winterhalder, R.; Von Burg, P.; Berardi Vilei, S.; Hayoz, S.; Rauch, D.; Roggero, E.; et al.